RespiriNTM

Progress novel assets (one FIH start) for non-tubercular mycobacteria that may act synergistically with bedaquiline and cytochrome bc drugs

Summary

Non-tuberculous mycobacteria (NTM) cause lung diseases that look like (but are not) tuberculosis (TB), mainly in people with weakened immune systems or patients with other lung diseases such as cystic fibrosis. NTM infections are caused by bacteria such as Mycobacterium avium complex and Mycobacterium abscessus, both of which are related to the TB-causing bacteria Mycobacterium tuberculosis. Cases of NTM disease are on the rise worldwide, and in regions where TB is largely under control, NTM is much more common than TB. Although treatments exist for the most common NTM infections, they do not always work well, and the complex treatment regimen can last as long as two years. Studies have shown that there are now cases of multi-drug resistant NTM. The goal of RespiriNTM is to find new drug candidates that could be part of a new, more efficient drug regimen for NTM with a shorter treatment time. The team will focus its efforts on the respiratory pathway of the bacteria that cause the disease. They will also carry out research to identify new drug targets that could be used to attack NTM bacteria. Finally, the team will study the factors that allow NTM bacteria to survive in humans.

RespiriNTM is part of the IMI AMR Accelerator Programme.

Achievements & News

Participants

  Show participants on map
EFPIA companies
  • Janssen Pharmaceutica Nv, Beerse, Belgium
Universities, research organisations, public bodies, non-profit groups
  • Academisch Ziekenhuis Leiden, Leiden, Netherlands
  • Kobenhavns Universitet, Copenhagen, Denmark
  • Medizinische Universitaet Wien, Vienna, Austria
  • Sorbonne Universite, Paris, France
  • Universiteit Antwerpen, Antwerp, Belgium
  • Universiteit Leiden, Leiden, Netherlands
Small and medium-sized enterprises (SMEs) and mid-sized companies (<€500 m turnover)
  • Bioversys AG, Basel, Switzerland
  • Ffund BV, Amsterdam, Netherlands
  • Mitologics, Romainville, France

Participants
NameEU funding in €
Academisch Ziekenhuis Leiden1 389 368
Bioversys AG280 000
Ffund BV234 046
Kobenhavns Universitet341 293
Medizinische Universitaet Wien848 750
Mitologics6 453
Sorbonne Universite795 500
Universiteit Antwerpen1 035 075
Universiteit Leiden757 500
Total Cost5 687 985